Pediatric acute myeloid leukemia—past, present, and future
D Reinhardt, E Antoniou, K Waack - Journal of clinical medicine, 2022 - mdpi.com
JCM | Free Full-Text | Pediatric Acute Myeloid Leukemia—Past, Present, and Future Next
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …
Article in Journal Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic …
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
L Gauthier, A Virone-Oddos, J Beninga, B Rossi… - Nature …, 2023 - nature.com
CD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid
leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting …
leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting …
CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
Developing CAR T cells for acute myeloid leukemia (AML) has been hampered by a paucity
of targets that are expressed on AML blasts and not on hematopoietic progenitor cells …
of targets that are expressed on AML blasts and not on hematopoietic progenitor cells …
NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity
RM Richards, F Zhao, KA Freitas, KR Parker, P Xu… - Blood Cancer …, 2021 - AACR
Chimeric antigen receptor (CAR) T cells hold promise for the treatment of acute myeloid
leukemia (AML), but optimal targets remain to be defined. We demonstrate that CD93 CAR T …
leukemia (AML), but optimal targets remain to be defined. We demonstrate that CD93 CAR T …
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy
S Willier, P Rothämel, M Hastreiter… - Blood, The Journal …, 2021 - ashpublications.org
Emerging immunotherapies such as chimeric antigen receptor T cells have advanced the
treatment of acute lymphoblastic leukemia. In contrast, long-term control of acute myeloid …
treatment of acute lymphoblastic leukemia. In contrast, long-term control of acute myeloid …
[HTML][HTML] The immune resistance signature of acute myeloid leukemia and current immunotherapy strategies
DJ Chandra, B Alber, JN Saultz - Cancers, 2024 - mdpi.com
Simple Summary Acute myeloid leukemia (AML) is an aggressive cancer of stem cells
originating in the bone marrow. Increasing evidence suggests that AML survival and relapse …
originating in the bone marrow. Increasing evidence suggests that AML survival and relapse …
Molecular-targeted therapy of pediatric acute myeloid leukemia
P Obszański, A Kozłowska, J Wańcowiat… - Molecules, 2022 - mdpi.com
Acute myeloid leukemia (AML) accounts for approximately 15–20% of all childhood
leukemia cases. The overall survival of children with acute myeloid leukemia does not …
leukemia cases. The overall survival of children with acute myeloid leukemia does not …
Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity
JT Zoine, K Immadisetty, J Ibanez-Vega, SE Moore… - Cell Reports …, 2024 - cell.com
The emergence of immune escape is a significant roadblock to developing effective chimeric
antigen receptor (CAR) T cell therapies against hematological malignancies, including acute …
antigen receptor (CAR) T cell therapies against hematological malignancies, including acute …
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 co-stimulation
A Vaidya, E Doherty, X Wu, S Huang… - …, 2022 - pmc.ncbi.nlm.nih.gov
The outcome of patients with acute myeloid leukemia remains poor, and immunotherapy has
the potential to improve this. T cells expressing chimeric antigen receptors or bispecific T …
the potential to improve this. T cells expressing chimeric antigen receptors or bispecific T …